Expertise in
4
conditions

Jens Kollmeier

Berlin, BE, DE 
Expertise in
4
conditions
Berlin, BE, DE 

Overview

Jens Kollmeier practices practicing medicine in Berlin, Germany.

Mr. Kollmeier is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Mesothelioma, Non-Small Cell Lung Cancer (NSCLC), Thymectomy, and Endoscopy.

He is actively involved in clinical research, co-authoring 77 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Berlin, BE, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Prospektiv Randomisierte Multizentrische Phase II-Studie Zur Metastasenresektion Von Lungenfiliae (Poor-prognosis) Beim Klarzelligen Nierenzellkarzinom +/- Adjuvante Sunitinibtherapie über 1 Jahr SMAT - AN 20/04 Der AUO
Prospektiv Randomisierte Multizentrische Phase II-Studie Zur Metastasenresektion Von Lungenfiliae (Poor-prognosis) Beim Klarzelligen Nierenzellkarzinom +/- Adjuvante Sunitinibtherapie über 1 Jahr SMAT - AN 20/04 Der AUO
Enrollment Status: Terminated
Publish Date: August 25, 2026
Intervention Type: Drug
Study Drug: Sunitinib
Study Phase: Phase 2
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2026
Intervention Type: Drug
Study Drugs: TAK-788, Pemetrexed, Cisplatin, Carboplatin
Study Phase: Phase 3
View 1 Less Clinical Trial

77 Total Publications

Delayed Solitary Adrenal Metastasis in Malignant Pleural Mesothelioma with Long-Term Survival under Immunotherapy.
Delayed Solitary Adrenal Metastasis in Malignant Pleural Mesothelioma with Long-Term Survival under Immunotherapy.
Journal: Pneumologie (Stuttgart, Germany)
Published: May 19, 2026

Frequently Asked Questions about Jens Kollmeier

Is Jens Kollmeier a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Jens Kollmeier is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jens Kollmeier participate in research or clinical trials?

Yes. Jens Kollmeier has published 77 articles and abstracts on conditions like Lung Cancer. You can view a list of Jens Kollmeier's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kollmeier's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile